Asset Dedication LLC’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.27M Buy
9,004
+44
+0.5% +$9.47K 0.14% 103
2026
Q1
$1.95M Sell
8,960
-1,756
-16% -$390K 0.14% 102
2025
Q4
$2.45M Sell
10,716
-384
-3% -$87.5K 0.16% 90
2025
Q3
$2.57M Sell
11,100
-680
-6% -$138K 0.17% 79
2025
Q2
$2.19M Buy
11,780
+712
+6% +$132K 0.16% 89
2025
Q1
$2.32M Sell
11,068
-758
-6% -$147K 0.19% 83
2024
Q4
$2.1M Sell
11,826
-4,388
-27% -$807K 0.17% 85
2024
Q3
$3.2M Sell
16,214
-4,162
-20% -$777K 0.22% 82
2024
Q2
$3.49M Sell
20,376
-403
-2% -$66.8K 0.24% 82
2024
Q1
$3.78M Buy
20,779
+8,713
+72% +$1.5M 0.28% 74
2023
Q4
$1.86M Sell
12,066
-2,329
-16% -$340K 0.15% 109
2023
Q3
$2.15M Buy
14,395
+1,120
+8% +$164K 0.18% 100
2023
Q2
$1.8M Sell
13,275
-641
-5% -$94K 0.15% 111
2023
Q1
$2.22M Buy
13,916
+514
+4% +$78.6K 0.21% 96
2022
Q4
$2.17M Buy
13,402
+1,210
+10% +$186K 0.22% 90
2022
Q3
$1.64M Buy
12,192
+379
+3% +$54.4K 0.18% 105
2022
Q2
$1.81M Buy
11,813
+50
+0.4% +$7.64K 0.27% 66
2022
Q1
$1.9M Sell
11,763
-2,195
-16% -$319K 0.21% 97
2021
Q4
$1.89M Buy
13,958
+5,168
+59% +$610K 0.23% 96
2021
Q3
$948K Buy
8,790
+1,712
+24% +$196K 0.12% 131
2021
Q2
$796K Buy
7,078
+358
+5% +$40.3K 0.12% 138
2021
Q1
$725K Sell
6,720
-438
-6% -$46.9K 0.16% 123
2020
Q4
$768K Sell
7,158
-295
-4% -$28.3K 0.15% 127
2020
Q3
$653K Buy
7,453
+544
+8% +$51.2K 0.14% 133
2020
Q2
$677K Sell
6,909
-614
-8% -$54.1K 0.18% 117
2020
Q1
$573K Buy
7,523
+1,287
+21% +$110K 0.17% 121
2019
Q4
$552K Buy
6,236
+386
+7% +$32K 0.16% 123
2019
Q3
$445K Buy
5,850
+1,646
+39% +$113K 0.15% 122
2019
Q2
$306K Sell
4,204
-208
-5% -$16.3K 0.1% 136
2019
Q1
$354K Sell
4,412
-13
-0.3% -$1.06K 0.12% 128
2018
Q4
$408K Sell
4,425
-2,364
-35% -$208K 0.17% 116
2018
Q3
$641K Sell
6,789
-391
-5% -$37.1K 0.24% 106
2018
Q2
$666K Sell
7,180
-150
-2% -$14.6K 0.23% 105
2018
Q1
$691K Buy
7,330
+751
+11% +$82.5K 0.34% 80
2017
Q4
$634K Buy
6,579
+2,472
+60% +$233K 0.26% 99
2017
Q3
$365K Sell
4,107
-138
-3% -$10.5K 0.18% 103
2017
Q2
$307K Sell
4,245
-339
-7% -$22.8K 0.15% 117
2017
Q1
$298K Sell
4,584
-90
-2% -$5.66K 0.16% 116
2016
Q4
$294K Buy
4,674
+402
+9% +$24.5K 0.17% 115
2016
Q3
$269K Buy
4,272
+100
+2% +$6.47K 0.17% 113
2016
Q2
$259K Sell
4,172
-834
-17% -$50.8K 0.18% 110
2016
Q1
$286K Sell
5,006
-389
-7% -$21.7K 0.21% 104
2015
Q4
$320K Buy
+5,395
New +$311K 0.21% 108

Other funds holding ABBV

Asset Dedication LLC's ABBV Position: Q2 2026 in Review

Asset Dedication LLC increased its AbbVie (ABBV) stake by 0.49% in Q2 2026, buying an estimated $9.47K and bringing the position to 9,004 shares worth $2.27M. The position accounts for 0.14% of the portfolio, ranked #103.

Asset Dedication LLC first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. The position peaked at $3.78M in Q1 2024. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Asset Dedication LLC held 9,004 shares of AbbVie worth $2.27M as of Q2 2026.
  • Asset Dedication LLC bought 44 AbbVie shares in Q2 2026, an estimated $9.47K.
  • AbbVie made up 0.14% of Asset Dedication LLC's portfolio in Q2 2026, its #103 holding.
  • Asset Dedication LLC first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
  • Asset Dedication LLC's AbbVie position peaked at $3.78M in Q1 2024.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Asset Dedication LLC's 13F filing for Q2 2026, filed 30 Jul 2026.